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Background and aims  
Biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis 
(PSC) have not been firmly established. Enhanced Liver Fibrosis (ELF) test was 
previously reported to predict outcome in PSC. We aimed to validate the prognostic 
utility of ELF test in an independent, multicenter, retrospective PSC study population. 
Methods 
We collected serum samples from PSC patients from seven countries. We estimated 
rates of transplant-free survival by the Kaplan–Meier method, used Cox proportional 
hazards regression to explore the association between ELF test and clinical outcome 
and determined prognostic performance of ELF test by computing the area under the 
receiver operating characteristic (AUC-ROC) curve. 
Results 
The final analysis included 534 PSC patients (61% males). Features of autoimmune 
hepatitis or concomitant inflammatory bowel disease affected 44 (8%) and 379 (71%) 
patients, respectively. ELF test levels were higher in patients reaching the combined 
endpoint liver transplantation or death (median 10.9 [interquartile range (IQR) 9.8-
12.1]; n=24 deaths, 79 liver transplantations) compared to those censored (8.8 [IQR 
8.0-9.8]); p<0.001. ELF test expressed as mild, moderate and severe fibrosis was 
significantly associated with the risk of reaching the endpoint (p<0.001). ELF test 
independently predicted clinical outcome (Hazard ratio 1.31; 95% confidence interval 
[1.05-1.65]; p=0.018), and enabled good discrimination between PSC patients with 





Our retrospective data validates the predictive utility of ELF test for clinical outcomes 
in PSC. The clinical utility of biomarkers for fibrosis in patients with PSC should be 
assessed in prospective patient cohorts. 
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Key Points 
• Primary sclerosing cholangitis (PSC) is a progressive biliary disease lacking 
medical treatment with currently no established tools to predict prognosis in 
the individual patient. The lack of biomarkers for risk stratification is an 
important obstacle to the development of therapy. 
• The Enhanced Liver Fibrosis (ELF®) test was previously reported to predict 
clinical outcome in two Norwegian PSC cohorts independently of clinical risk 
scores. 
• Our data confirm, in a large, international, multicenter cohort, that ELF test 
predicts prognosis in PSC and may be used for risk stratification in clinical 
follow-up. 






Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease of 
unknown etiology resulting from the development of fibrotic strictures throughout the 
biliary tree. Eventually most patients develop fibrosis, cirrhosis and end-stage liver 
failure.[1] The only curative treatment modality is liver transplantation,[2] and PSC is 
the number one indication of liver transplantation within the spectrum of autoimmune 
and cholestatic liver disease.[3]  
 There is an unmet need for medical therapeutic options in the management of 
PSC patients. However, the development of new treatment strategies is hampered by 
the lack of prognostic markers and the overall slowly progressive nature of the 
disease, which results in difficulties to demonstrate treatment effects in clinical 
trials.[4]  
Liver fibrosis is a well-established predictor of disease outcome in PSC – 
exemplified by the implementation of liver histology and liver elastography in several 
prognostic models for PSC.[5–9] Over recent years, non-invasive methods to measure 
liver fibrosis have gained interest, including the use of serum biomarkers. The 
Enhanced Liver Fibrosis (ELF) test is a promising panel, incorporating three direct 
serum markers of fibrosis in an algorithm: hyaluronic acid, tissue inhibitor of 
metalloproteinases-1 (TIMP-1), and amino-terminal pro-peptide of type III pro-
collagen (PIIINP).[10,11] The ELF test accurately predicted significant liver fibrosis and 
furthermore predicted clinical outcome in several independent populations and in 
patients with various etiologies of chronic liver disease.[12–16]  
Recently, the prognostic value of the ELF test in PSC was assessed in two 
independent Norwegian PSC cohorts.[17] The ELF test consistently predicted liver 




scores.[17] In the present study, we aimed to validate the prognostic value of the ELF 
test in a large, multi-center PSC cohort. 
 
PATIENTS AND METHODS 
 
Study design, patient and tissue requirements  
PSC patients from seven centers in Europe and Canada were included: Helsinki 
University Hospital, Finland; Medical University of Warsaw, Poland; University of 
Calgary, Canada; Hôpital Saint Antoine, Paris, France; Hospital Clínic, Barcelona, 
Spain; Humanitas Clinical and Research Center, Rozzano, Italy, and the Academic 
Medical Center, Amsterdam, the Netherlands. PSC diagnosis was established 
according to the EASL clinical practice guidelines.[18] A diagnosis of PSC with 
features of autoimmune hepatitis (AIH) was made in keeping with expertise of the 
contributing center. The individual centers received ethical approval at the national 
level (Suppl. Table 1). All patients provided written, informed consent. 
Clinical data had previously been collected in the context of the International 
PSC Study Group. Where missing, additional clinical and laboratory data as well as 
data on liver biochemistry at time of the ELF test sample withdrawal (+/- 1 month) 
were retrospectively retrieved from patient files by the participating centers. IBD 
diagnosis was based on findings at colonoscopy and histology.  
Frozen serum samples were collected from 577 PSC patients. For 
determination of the ELF test, serum samples were analyzed by the commercially 
available ELF®Test (Siemens Medical Solutions Diagnostics Inc., Tarrytown, NY, 








Patient characteristics and laboratory values were expressed as median and 
interquartile range. Dichotomous variables were expressed as percentage (%) of the 
cohort. Since reference values of biochemical variables differed slightly between 
centers according to local instrumentation and kit, all biochemical variables were 
expressed as fold change the upper or lower limit of normal of each center. 
Biochemical values showing a skewed distribution were transformed using natural 
logarithmic transformation. Continuous variables were tested for normal distribution, 
and for comparison between groups the Student’s t-test or the Mann-Whitney U test 
was applied, as appropriate.  
Time of PSC diagnosis was defined by the first pathological cholangiogram. A 
composite endpoint composed by all-cause death and liver transplantation was 
defined.[17] Survival time was calculated as the interval between the date of serum 
withdrawal for ELF test and the date of reaching the composite endpoint, or, in case 
no endpoint was reached, date of last follow-up. 
Rates of transplant-free survival were estimated for three groups of fibrosis 
severity: mild, moderate and severe fibrosis defined as ELF test level <7.7, ≥7.7 to 
<9.8, and ≥9.8, respectively, as recommended by the manufacturer; crude risk was 
compared using log-rank test. Due to the small number of patients with a follow-up 





Univariable Cox proportional hazards model was used to assess the potential 
association of all clinical and biochemical variables with the occurrence of the 
endpoint. Factors that were significantly associated (P<0.05) with outcome in the 
univariable analysis were entered into the multivariable model. Using stepwise 
forward multivariable Cox regression analysis, the independent prognostic value of 
ELF test was assessed. The criterion for retaining predictors was a p-value <0.05. 
The proportionality during follow-up for risk prediction with ELF test as a continuous 
variable was found acceptable for all assays and cohorts as tested by the cox.zph 
function in R. 
The prognostic performance of ELF test was determined by computing the 
area under the receiver operating characteristic (ROC) curve. The optimal threshold 
to distinguish patients that experience an endpoint from those that do not, was 
calculated by Youden’s index – the maximum total sensitivity and specificity. 
Correlations between ELF test and other laboratory variables were assessed 
by Spearman’s rank correlation test.  
Statistical analyses were performed using SPSS version 22.0 software (SPSS, 
Chicago, IL); calculation of the net reclassification index and testing for the 
proportional hazards assumptions were performed in R (R Foundation for Statistical 








Serum samples of 577 PSC patients were received from the participating centers. A 
total of 17 samples were excluded because of insufficient serum volumes and five 
samples were excluded due to inability to calculate the ELF test because of 
undetectable (<0.50 ng/mL) or high (out of range despite 1:10 dilution) PIIINP levels 
in repeated analyses (n=3 and 1, respectively), or (for one patient) widely discrepant 
results from duplicate samples  (hyaluronic acid 42.02 vs 11.79, PIIINP 21.85 vs 2.94 
and TIMP1 331.9 vs 58.2). In addition, 21 patients diagnosed with small duct PSC 
were excluded to reduce heterogeneity. The final number of patients included was 
534. Out of these, 24 patients died and 79 underwent liver transplantation (Table 1). 
The median age at PSC diagnosis was 34 years (IQR 25-45), and 379 (71%) 
patients suffered from concurrent IBD, out of which 289 (54% of the total study 
population) were classified as ulcerative colitis. The median disease duration at time 
of serum withdrawal for ELF test analysis was 57 months (IQR 28-111). An overview 
of baseline characteristics and laboratory values at time of ELF test sample 
withdrawal is provided in Table 1.  
 
Differentiation of PSC phenotype by ELF test score 
The ELF test was higher in patients reaching an endpoint than in those censored, 
with medians of 10.9 (IQR 9.8-12.1) and 8.8 (IQR 8.0-9.8), respectively; p<0.001. 
ELF was elevated in men compared to women (median 9.2 [IQR 8.3-10.7] and 8.8 
[IQR 8.0-10.0], respectively; p=0.006), and associated with more advanced disease 




transplants in males compared to females (data not shown). The median ELF test did 
not differ between patients with and without inflammatory bowel disease (median 9.1 
[IQR 8.2-10.5] and 9.2 [IQR 8.2-10.4], respectively; p=0.936. 
 A total of 19 (4%) patients developed hepatobiliary malignancies; 3 gallbladder 
carcinomas, 2 hepatocellular carcinomas and 15 cholangiocarcinomas (CCA). Ten 
patients were diagnosed with CCA after serum withdrawal for ELF test, with a median 
interval of 14 months [IQR 11-24]. This subgroup of patients with CCA had a 
significantly higher ELF test than patients without CCA, median 10.7 [IQR 9.3-11.4] 
and 9.1 [IQR 8.2-10.4], respectively; p=0.035. The ELF test was not significantly 
different between five patients who had a diagnosis of CCA at ELF test serum 
withdrawal and patients with no CCA (10.5 [IQR 9.2-11.8] and 9.1  [IQR 8.0-10.2], 
respectively, p=0.35). 
 
Prognostic performance of the ELF test 
The manufacturer of the ELF test defines three groups of fibrosis severity based on 
ELF scores, i.e. none to mild, moderate, and severe (ELF score <7.7, ≥7.7 to <9.8 
and ≥9.8, respectively). There was a significant association between the ELF test 
subdivided into three groups based on these definitions (N=81 mild, 257 moderate 
and 178 severe fibrosis, respectively), and the risk of reaching the clinical composite 
endpoint all cause death and liver transplantation, p<0.001 (Figure 1). Additional 
Kaplan-Meier survival analysis when applying the composite endpoint PSC related 
death and liver transplantation showed a comparable result (Supplementary Figure 
1). 
When re-classifying PSC patients in low-risk and high-risk groups based on 




low risk patients and PSC patients. There were significantly more endpoints in the 
high compared to the low risk group (67 [37.6%] vs 23 [6.8%]; odds ratio (OR) 6.72 
[95%CI 4.14-10.90]), and this difference persisted if patients with hepatobiliary 
malignancy were excluded (n=58 vs 21 endpoints, OR 8.13 [4.71-14.03]). The risk of 
liver transplantation alone was also higher in the high risk compared to low risk group 
(n=54 vs 19, OR 5.85 (95%CI 3.47-9.86). The high risk group had longer median 
PSC duration at ELF test withdrawal compared to the low risk group, i.e. 76 
[interquartile range, (IQR) 30-121] and 51 [IQR 28-103] months, respectively; 
p=0.039). 
The ELF test had a good discriminative ability to distinguish patients that reach 
an endpoint from those that do not, with an area under the curve (AUC) of 0.80 (95% 
CI 0.75-0.85) p<0.001 (Figure 2). The optimal threshold of the ELF test to 
discriminate between patients that do, and do not reach an endpoint was 9.85 
(sensitivity 0.74 [0.64, 0.83], specificity 0.75 [0.71, 0.79], Youden’s index: 0.50). 
Application of the previously identified cut-off levels for ELF test in PSC of 11.1 
yielded increased specificity at the cost of reduced sensitivity (sensitivity 0.43, 
specificity 0.90, respectively). The discriminatory ability of the ELF test was not 
significantly different from that of bilirubin (AUC 0.83) or APRI score (AUC 0.80) but 
significantly better than Fib4 (AUC 0.73, p=0.02) and albumin (AUC 0.67, p=0.005) 
(Suppl. Fig. 2). 
  
Clinical and biochemical prognostic indicators of transplant-free survival  
Univariable Cox regression analysis showed a significant association between 
transplant-free survival and the following variables: sex, aspartate aminotransferase, 




normalized ratio, platelet count, AST to platelet ratio index (APRI), and the ELF test 
(Table 2). Subsequent multivariable analysis including all of the variables showing 
associations in the univariable analyses, demonstrated an independent prognostic 
value of the ELF test (hazard ratio (HR) 1.31 [95% CI 1.05-1.63], p=0.016; Table 3). 
In addition to the ELF test, total bilirubin and albumin remained independently 
associated with outcome in multivariable analysis (Table 3).  
 
DISCUSSION 
This study confirms the prognostic value of ELF test in the prediction of clinical 
outcome in PSC, in a large, well characterized, multicenter PSC cohort. We found 
that the ELF test was a strong predictor of clinical outcome as defined by liver 
transplantation or death independent of other clinical and laboratory variables 
associated with outcome. One unit increase in the ELF test was associated with a 
1.31-fold increased risk of death or liver transplantation. 
By subdividing ELF test results into three groups of fibrosis severity based on 
cut-off levels provided by the manufacturer, we showed that patients with PSC can 
be stratified into low, intermediate and high risk groups for the composite endpoint of 
death or liver transplantation. Although the difference between these three groups 
was statistically significant, a comparison of the Kaplan-Meier curves of the present 
study with the original results, suggested a suboptimal ability to distinguish mild from 
moderate disease.[17] This may in part be explained by the use of thresholds not 
originally developed to differentiate disease stages in a biliary disorder with a porto-
portal fibrosis pattern like PSC. However, the manufacturer’s optimal cut-off to 
discriminate between patients with and without severe fibrosis (9.8) was similar to the 




endpoint as estimated by the Youden’s index in our study population (9.85) and 
seems to be a robust cut-off level to identify high-risk patients. Previously, higher 
optimal cut-off values for ELF of 11.1 and 11.2 were identified in two PSC 
populations;[17] application of any of these cut-off levels in the present study 
population yielded increased specificity at the cost of reduced sensitivity compared to 
a cut-off of 9.8. Further studies should aim to define clinically meaningful PSC-
specific cut-off levels that might also robustly identify a low-risk group. 
 We report increased ELF test in patients later diagnosed with CCA (n=10) in 
line with previous results.[17] The ELF test was not significantly increased in five 
patients who had a diagnosis of CCA at serum withdrawal for ELF test analysis. 
Excluding patients with CCA from the analyses did not alter the association of ELF 
test with clinical outcome (data not shown). The present data cannot resolve the 
question of whether the association between ELF test and CCA in PSC reflects more 
advanced disease in these patients or results from the excessive fibrotic response in 
the surrounding tissue of the “scirrhous” type of CCA often found in PSC, potentially 
an early risk sign for CCA.[20,21] Dedicated analyses seem warranted to further 
explore the association between ELF test and CCA. 
In addition to the ELF test, several other established biomarkers of fibrosis 
have been used in other liver diseases, including the APRI score,[22] Fibrosis-4-
score,[23] and FibroTest.[24] The diagnostic performance of these biomarkers along 
with ELF test and liver histology was assessed in a PSC patient population that was 
included in a randomized trial of simtuzumab.[25] The ELF test accurately diagnosed 
advanced fibrosis and cirrhosis (sensitivity 97% and 79%, specificity 9% and 64%, 
respectively) whereas FibroTest, APRI and FIB-4 scores all had lower sensitivities 




cirrhosis.[25] These results corroborate previous findings showing that baseline APRI 
and FIB-4 did not identify patients with higher risk of developing liver related events 
while ELF test did.[16]  
The most widely used prognostic model in PSC research is the Mayo Risk 
model; however, this model notably failed to predict adverse outcomes in high-dose 
ursodeoxycholic acid studies. We could not compare ELF test to the Mayo risk score 
because of lack of reliable data on variceal bleeding.  However, our data show that 
the ELF test predicted clinical outcome independently of all individual biochemistries 
identified as relevant through univariable analyses. These findings suggest that ELF 
test has an independent prognostic value, and that the combination of the ELF test 
and clinically derived prognostic models in PSC might increase prognostic power. 
Such composite models warrant further research. As PSC in its early stages primarily 
is an inflammatory disease of the biliary epithelium, it would be interesting to assess 
whether addition of an inflammatory marker would improve prognostication in the 
low-risk groups defined by ELF. Furthermore, it would be interesting to explore 
whether compound assessments combining ELF test with ultrasound- or MR-based 
liver stiffness measurements, could provide incremental prognostic information. 
Whether the ELF test reflects merely fibrosis stage or also disease intensity 
has not been firmly established. The original paper on the development of the ELF 
test describes excellent correlation between ELF test and degree of fibrosis, but only 
moderate correlation with histological grade, suggesting that it is mostly a stage 
marker.[10] Exploring the dynamics of ELF test results over time, as well as its ability 
to measure treatment effect in terms of fibrosis regression is warranted to establish 
the ELF test’s applicability in clinical practice and its usefulness to function as a 




Proving the clinical value of a new test, and deciding when and how to 
implement a new test in clinical practice are important challenges. To be clinically 
useful, a biomarker should be measurable by available, reliable analytical methods, 
add new information compared to existing markers, and guide patient 
management.[26] The pivotal criterion is the consistency and strength of the 
association between the biomarker and the outcome, and the extent to which the 
new marker improves prognostication by addition to or replacing established tools. 
External validation in at least two adequately-sized prospective studies is advised for 
prognostic markers in cardiac disease.[26] The ELF test is commercially available and 
well validated for other liver diseases.[14–16] Furthermore, ELF test has shown 
consistent, strong association with clinical outcome independent of clinical risk 
models in two independent monocenter PSC panels, and now in a large, multicenter 
PSC patient panel.[17] The ELF test has shown incremental value when added to the 
clinically based Mayo risk score. However, prospective validation is lacking and 
further comparisons and combinations with other biomarkers and risk scores merit 
investigation before implementation of ELF in clinical practice. 
The retrospective nature and the lack of radiological or histological staging 
represent limitations to the present study. The choice of all-cause death and liver 
transplantation as combined end-point may also introduce elements of uncertainty 
based on variable indications for liver transplantation. However, in lack of gold 
standards, clinical outcome is a valid variable against which ELF can be 
benchmarked. Assessment of the dynamics of the ELF test over the disease course 
was not feasible because of the cross-sectional design of this study.  
 In conclusion, our data from a large, international, multicenter cohort confirm 




PSC. Further investigations of the clinical utility of the ELF test in prospective 
cohorts, is an important next step before general implementation in clinical practice 
can be advocated. Clinically meaningful PSC-specific cut-off values for risk 
stratification should be established to facilitate clinical use. Further refinements of the 
components of the ELF test, or compound assessments combining the ELF test with 
clinical scores and imaging, are avenues that should be explored in order to optimize 
our ability to capture risk. In an era with a considerable clinical need to identify 
surrogate markers of liver fibrosis and prognosis to measure treatment effect in 
clinical trials for PSC, investigations aiming at exploring the potential utility of the ELF 
test in this regard should be integrated in clinical trials.  
 
ACKNOWLEDGEMENTS 






1. Williamson K, Chapman C. Primary sclerosing cholangitis: a clinical update. Br. 
Med. Bull. 2015; 114:56–64.  
2. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. 
Lancet. 2013; 382:1587–99.  
3. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver 
transplantation in Europe. A report from the European Liver Transplant Registry 
(ELTR). J. Hepatol. 2012; 57:675–688.  
4. Ponsioen CY, Chapman RW, Chazouillères O, et al. Surrogate endpoints for 
clinical trials in primary sclerosing cholangitis ; review and results from an 
International PSC Study Group consensus process. Hepatology. 2016; 63:1357–67.  
5. Wiesner R, Grambsch P, Dickson E, et al. Primary sclerosing cholangitis: natural 
history, prognostic factors and survival analysis. Hepatology. 1989; 10:430–6.  
6. Farrant J, Hayllar K, Wilkinson M, et al. Natural history and prognostic variables in 
primary sclerosing cholangitis. Gastroenterology. 1991; 100:1710–7.  
7. Dickson E, Murtaugh P, Wiesner R, et al. Primary sclerosing cholangitis: 
refinement and validation of survival models. Gastroenterology. 1992; 103:1893–901.  
8. Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 
Swedish patients with primary sclerosing cholangitis. Gut. 1996; 38:610–615.  
9. Corpechot C, Gaouar F, El Naggar A, et al. Baseline values and changes in liver 
stiffness measured by transient elastography are associated with severity of fibrosis 
and outcomes of patients with primary sclerosing cholangitis. Gastroenterology. 2014 
Apr; 146(4):970-9–6.  




of liver fibrosis: A cohort study. Gastroenterology. 2004 Dec; 127(6):1704–1713.  
11. Xie Q, Zhou X, Huang P, Wei J, Wang W, Zheng S. The performance of 
enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis. 
PLoS One. 2014 Apr; 9(4):e92772.  
12. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict 
clinical outcomes in patients with chronic liver disease. Gut. 2010 Sep; 59(9):1245–
51.  
13. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in 
primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008 
Nov; 48(5):1549–57.  
14. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in 
nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and 
exploring simple markers. Hepatology. 2008 Feb; 47(2):455–60.  
15. Parkes J, Guha IN, Roderick P, et al. Enhanced Liver Fibrosis (ELF) test 
accurately identifies liver fibrosis in patients with chronic hepatitis C. J. Viral Hepat. 
2011 Jan; 18(1):23–31.  
16. Irvine KM, Wockner LF, Shanker M, et al. The Enhanced liver fibrosis score is 
associated with clinical outcomes and disease progression in patients with chronic 
liver disease. Liver Int. 2016; 36:370–7.  
17. Vesterhus M, Hov JR, Holm A, et al. Enhanced Liver Fibrosis Score Predicts 
Transplant-Free Survival in Primary Sclerosing Cholangitis. Hepatology. 2015; 
62:188–197.  
18. European Association for the Study of the Liver. EASL Clinical Practice 





19. de Vries E, Wang J, Williamson KD, et al. A novel prognostic model for primary 
sclerosing cholangitis. Hepatology. 2015; 62:244A–245A.  
20. Lazaridis KN, Gores GJ. Primary Sclerosing Cholangitis and 
Cholangiocarcinoma. Semin. Liver Dis. 2006; 26:42–51.  
21. Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M. The 
Significance of Stromal Desmoplasia in Intrahepatic Cholangiocarcinoma: A Special 
Reference of “Scirrhous-type” and “Nonscirrhous-type” Growth. Am. J. Surg. Pathol. 
1999; 23:892–902.  
22. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-
to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-
analysis. Hepatology. 2011; 53:726–736.  
23. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive 
index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 
2006; 43:1317–1325.  
24. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. 
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a 
prospective study. Lancet. 2001; 357:1069–1075.  
25. Bowlus CL, Muir P, Guha IN, et al. Validation of serum fibrosis marker panels in 
patients with primary sclerosing cholangitis (PSC) in a randomized trial of 
simtuzumab. Hepatology. 2015; 62:519A.  
26. Morrow DA, De Lemos JA. Benchmarks for the assessment of novel 




Table 1. Patient characteristics and clinical outcomes 
 Total 
panel 
 Risk groups defined by ELF test using 
manufacturer’s cutoff levels 
   <7.7  ≥7.7 - 
<9.8 
 ≥9.8  
Patient characteristics  N  N  N Median(IQR)  
or N (%) 
N 
N 534  85  266  183  
Male [n (%)] 324  (61)  42 (49)  156 (59)  126 (69)  
Age at ELF withdrawal 







257 41 (30-53) 178 
Age at diagnosis PSC 
(years) [median (IQR)] 






266 34 (24-44) 183 
AIH overlap  [n (%)]  44    (8) 534 6 (7) 85 24 (9) 266 14 (8) 183 
Inflammatory bowel 
disease [n (%)] 
379  (71) 534 59 (69) 85 185 (70) 266 135 (74) 183 
     Ulcerative colitis [n (%)] 289  (54) 534 42 (49) 85 139 (52) 266 108 (59) 183 
     Crohn’s disease [n (%)] 63    (12) 534 15 (18) 85 31 (12) 266 17 (9) 183 
     Unspecified [n (%)] 27    (5) 534 2 (2) 85 15 (6) 266 10 (6) 183 
Disease duration at ELF 
withdrawal (months) 
[median (IQR)] 









Follow up time from ELF 
withdrawal (months) 
[median (IQR)] 






257 17 (5-38) 178 
Death [n (%)] 24    (5) 534 0 (0) 85 7 (3) 266 17 (9) 183 
PSC related death [n (%)] 15    (3) 534 0 (0) 85 4 (2) 266 11 (6) 183 
Liver transplantation [n 
(%)] 
79    (15) 534 2 (2) 85 22 (8) 266 55 (30) 183 
   Liver transplantation for 
end-stage liver disease  
35 (7) 534 1 (1) 85 12 (5) 266 22 (12) 183 
   Liver transplantation for 
CCA or high-grade 
dysplasia 
4(1) 534 0 (0) 85 2 (1) 266 2 (1) 183 
   Liver transplantation for 
intractable symptoms 





AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ALP, alkaline phosphatase; ALT, 
alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate 
aminotransferase; CI, confidence interval; ELF, enhanced liver fibrosis score; HR, Hazard 
ratio; INR, International normalized ratio; IQR, inter quartile range; PSC, primary sclerosing 
cholangitis; xLLN = times lower limit; xULN = times upper limit of normal. 
   Liver transplantation, 
indication not available 
28 (5) 534 1 (1) 85 4 (2) 266 23 (13) 183 
Laboratory values at time 
of ELF withdrawal 
        



































































































































Table 2. Predictors of transplant-free survival in PSC assessed by univariable 
Cox regression analysis 
 
 Univariable analysis 







Sex  0.53 (0.33, 0.84) 0.007 534 
Age at ELF withdrawal 0.99 (0.98, 1.01) 0.27 516 
Age at PSC diagnosis 0.99 (0.98, 1.01) 0.30 534 
Co-existing IBD 1.34 (0.83, 2.17) 0.23 534 
Co-existing IBD phenotype 0.99 (0.77, 1.29) 0.96 534 
PSC duration at ELF 
withdrawal (months) 
1.00 (1.00, 1.00) 0.90 516 
Auto-immune hepatitis overlap 0.79 (0.34, 1.80) 0.57 534 
Center of inclusion 1.12 (0.99, 1.26) 0.07 534 
AST  3.19 (2.24, 4.54) <0.005 338 
ALT  2.18 (1.61, 2.96) <0.005 351 
ALP  2.92 (2.03, 4.18) <0.005 362 
Total bilirubin  4.28 (2.81, 6.53) <0.005 339 
Albumin 0.11 (0.04, 0.28) <0.005 302 
International normalized ratio 4.08 (1.99, 8.38) <0.005 257 
Platelet count 0.40 (0.25, 0.63) <0.005 331 
Creatinine 0.37 (0.05, 2.51) 0.31 299 
APRI 1.45 (1.27, 1.65) <0.005 304 
ELF test 1.77 (1.58, 1.99) <0.005 534 
 
AST, ALT ALP and total bilirubin were transformed by the natural logarithm prior to 
regression analyses due to a right-skewed distribution. AIH, autoimmune hepatitis; ALT, 
alanine aminotransferase; ALP, alkaline phosphatase; APRI, AST to platelet ratio index; 
AST, aspartate aminotransferase; CI, confidence interval; ELF, enhanced liver fibrosis score; 








Table 3. Multivariable Cox regression analysis, assessing independent 
predictors of transplant-free survival in PSC patients. The analysis included all of 
the variables showing significant associations with transplant-free survival in the 
univariable analyses (sex, AST, ALT, ALP, albumin, bilirubin, INR, thrombocytes and 
ELF test) for n=219 patients with complete data available. Omitting INR from the 
analysis in order to increase the number of patients with available data, yielded the 
same final model with similar HRs in n=256 patients (data not shown). Laboratory 
values were entered using value times the upper or lower limit of normal as 
appropriate. AST, ALT ALP and total bilirubin were transformed by the natural 
logarithm prior to regression analyses due to a right-skewed distribution. ALT, alanine 
aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; CI, 
confidence interval; ELF, enhanced liver fibrosis score; HR, Hazard ratio; INR, 




                                  
HR    (95% CI) 
 
               
p-
value 
Total bilirubin  2.91 (1.50-5.64) 0.002 
Albumin 0.12 (0.03-0.50) 0.004 










Figure 1. Prediction of transplant-free survival by the ELF test.  
The figure shows Kaplan-Meier curves of time to transplantation or death for PSC patients (n=516) 
stratified into groups of mild, moderate and severe fibrosis defined as ELF <7.7, ≥7.7 to <9.8, and 
≥9.8, respectively, as recommended by the manufacturer; illustrating shorter survival in patients in the 
group with severe fibrosis as defined by the ELF test compared to patients with intermediate and low 




























Figure 2. Prognostic performance of the ELF test.  
The prognostic performance of the ELF test was assessed by analysis of the area under the curve of 
the receiver operator characteristics curve (AUC-ROC). The ELF test distinguished patients that 
reached liver transplantation or death from those that did not with an area under the curve of 0.80 
(95% CI [0.75, 0.85]), p<0.001, demonstrating a good discriminatory ability. The optimal threshold of 
the ELF test to discriminate between patients that did, and did not reach an endpoint was 9.85 
(sensitivity 0.74, specificity 0.75). AUC-ROC, area under the curve of the receiver operator 
characteristics curve; ELF test, enhanced liver fibrosis test; PSC, primary sclerosing cholangitis. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
AUC=0.80 
P<0.001 
